Bioprogress General Discussion

Inyx wagers its success on its treatments for a particular niche market: miseries. The company makes over-the-counter and prescription allergy, dermatological, respiratory, and topical pharmaceuticals and a variety of drug delivery technologies through its Inyx Pharma subsidiary. The company formulates, manufactures and packages finished products according to third-party customer specifications from its facility in the UK. Its Exaeris subsidiary performs the company's international marketing and distrubution functions. Founded in 2000 as a thoroughbred horse racing company called Doblique, in 2003 the company ponied up the funds for Inyx Pharma and changed focus. Larry Stockhamer owns 26% of the company.